tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

OCUL Stock Latest News

Promising Developments and Strategic Advancements Support Buy Rating for Ocular Therapeutix
RatingsPromising Developments and Strategic Advancements Support Buy Rating for Ocular Therapeutix
13d ago
OCUL
Ocular Therapeutix: Strategic Advancements and Market Potential Drive Buy Rating
PremiumRatings
Ocular Therapeutix: Strategic Advancements and Market Potential Drive Buy Rating
13d ago
OCUL
Ocular Therapeutix receives FDA agreement under SPA for trial of AXPAXLI
PremiumThe Fly
Ocular Therapeutix receives FDA agreement under SPA for trial of AXPAXLI
14d ago
OCUL
Optimistic Buy Rating for Ocular Therapeutix Driven by Promising Clinical Trials and Strategic Decisions
PremiumRatings
Optimistic Buy Rating for Ocular Therapeutix Driven by Promising Clinical Trials and Strategic Decisions
18d ago
OCUL
Ocular Therapeutix price target lowered to $20 from $22 at Scotiabank
PremiumThe Fly
Ocular Therapeutix price target lowered to $20 from $22 at Scotiabank
19d ago
OCUL
Ocular Therapeutix Reports Q2 2025 Financial Results
PremiumCompany AnnouncementsOcular Therapeutix Reports Q2 2025 Financial Results
20d ago
OCUL
Ocular Therapeutix Earnings Call: Positive Outlook Amid Trial Progress
Premium
Company Announcements
Ocular Therapeutix Earnings Call: Positive Outlook Amid Trial Progress
20d ago
OCUL
Ocular Therapeutix reports Q2 EPS (39c), consensus (35c)
Premium
The Fly
Ocular Therapeutix reports Q2 EPS (39c), consensus (35c)
21d ago
OCUL
Ocular Therapeutix sees cash runway into 2028
PremiumThe Fly
Ocular Therapeutix sees cash runway into 2028
21d ago
OCUL
OCUL Upcoming Earnings Report: What to Expect?
PremiumPre-Earnings
OCUL Upcoming Earnings Report: What to Expect?
23d ago
OCUL
Ocular Therapeutix Approves Key Amendments at Annual Meeting
PremiumCompany Announcements
Ocular Therapeutix Approves Key Amendments at Annual Meeting
3M ago
8K
OCUL
Ocular Therapeutix’s Promising Clinical Trials and Strategic Advancements Justify Buy Rating
PremiumRatings
Ocular Therapeutix’s Promising Clinical Trials and Strategic Advancements Justify Buy Rating
3M ago
OCUL
Strong Buy Rating for Ocular Therapeutix Driven by Promising Axpaxli Program and Market Potential
PremiumRatingsStrong Buy Rating for Ocular Therapeutix Driven by Promising Axpaxli Program and Market Potential
3M ago
OCUL
Ocular Therapeutix’s Promising Developments and Strategic Execution Justify Buy Rating
Premium
Ratings
Ocular Therapeutix’s Promising Developments and Strategic Execution Justify Buy Rating
3M ago
OCUL
Ocular Therapeutix to close enrollment this week for SOL-R
Premium
The Fly
Ocular Therapeutix to close enrollment this week for SOL-R
3M ago
OCUL
Ocular Therapeutix: Promising Pipeline and Strategic Developments Justify Buy Rating Despite Current Financial Challenges
PremiumRatings
Ocular Therapeutix: Promising Pipeline and Strategic Developments Justify Buy Rating Despite Current Financial Challenges
4M ago
OCUL
Ocular Therapeutix Advances in Retinal Treatment Trials
PremiumCompany Announcements
Ocular Therapeutix Advances in Retinal Treatment Trials
4M ago
OCUL
Strategic Advancements and Financial Updates Drive Buy Rating for Ocular Therapeutix
PremiumRatings
Strategic Advancements and Financial Updates Drive Buy Rating for Ocular Therapeutix
4M ago
OCUL
Optimistic Buy Rating for Ocular Therapeutix Driven by Streamlined Trials and Promising FDA Engagement
PremiumRatings
Optimistic Buy Rating for Ocular Therapeutix Driven by Streamlined Trials and Promising FDA Engagement
4M ago
OCUL
Morning Movers: Skechers surges following take-private deal
PremiumThe FlyMorning Movers: Skechers surges following take-private deal
4M ago
HHH
SKX
Ocular Therapeutix reports Q1 EPS (38c), consensus (28c)
Premium
The Fly
Ocular Therapeutix reports Q1 EPS (38c), consensus (28c)
4M ago
OCUL
Ocular Therapeutix sees cash runway into 2028
Premium
The Fly
Ocular Therapeutix sees cash runway into 2028
4M ago
OCUL

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >